Advanced Biomed Leads Biotech Gainers With Over 200% Weekly Surge

EarningsCorporate Action

โดย RTTNews·Read original

Summary · why it matters

Advanced Biomed shares rallied as much as 211% this week, leading a group of biotech gainers that also included Novocure, Medpace, and others. Advanced Biomed, which has not yet commenced commercial sales, soared from $6.71 to an intraday high of $20.87 before closing Thursday at $16.78, up 36.98% on the day. Novocure surged more than 28% after reporting second-quarter total net revenues of $183.6 million, a 16% year-over-year increase, and raising its full-year 2026 revenue guidance to $710 million to $725 million from a prior range of $690 million to $710 million. Medpace gained more than 14% following second-quarter revenue of $707.3 million, up 17.2% from the prior-year period, and a full-year 2026 revenue forecast of $2.805 billion to $2.885 billion. Other notable movers included SciSparc, up over 20% on no specific news, Agenus, up more than 11% after announcing an oversubscribed private placement of up to $340 million, and AgomAb Therapeutics, up more than 11% ahead of expected clinical data readouts.